Key result
IVIG yields gradual improvement of muscle weakness in a case of hepatitis E-associated Guillain-Barré syndrome.
Why the study?
The number of hepatitis E virus-associated Guillain-Barré syndrome cases has been increasing, highlighting the need to consider HEV infection in GBS patients with relevant exposure or liver dysfunction.
Case Report (n=1)
No
Hepatitis E virus infection should be considered as a potential trigger in patients presenting with Guillain-Barré syndrome, particularly those with a history of pork consumption or liver dysfunction.
Suggests possible IVIG benefit in hepatitis E-associated Guillain-Barré syndrome; hypothesis-generating and should not yet change practice.
An 81-year-old man presented with limb weakness and dysesthesia approximately 10 days after eating pork liver. His neurological examination revealed muscle weakness predominantly centered in the lower limbs and absence of deep tendon reflex, and cerebrospinal fluid analysis showed elevated proteins with normal cell counts. Furthermore, his nerve conduction studies revealed distal motor latency prolongation and decreased motor nerve conduction velocities in the bilateral median, ulnar, tibial, and peroneal nerves. Lastly, serological analysis was performed for hepatitis E virus markers, resulting in a positive result for hepatitis E virus (HEV)-IgA antibody and HEV-RNA. Given all these findings, the patient was diagnosed with acute HEV-associated Guillain-Barré syndrome (GBS), and intravenous immunoglobulin treatment was administered for five days. Following this, muscle weakness and dysesthesia gradually improved. As observed in this report, the number of HEV-associated GBS cases has been increasing over the past several years. Therefore, HEV infection should be considered in GBS patients who have a history of pork consumption or have been suffering from liver dysfunction.
No takes yet. Share an insight, caveat, or question.
Tarisawa et al. (2021) conducted a case report in Guillain-Barré syndrome following hepatitis E virus infection (n=1). Intravenous immunoglobulin (IVIg) was evaluated on Clinical improvement of muscle weakness and dysesthesia. Intravenous immunoglobulin treatment led to the gradual improvement of muscle weakness and dysesthesia in an 81-year-old man with acute hepatitis E virus-associated Guillain-Barré syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: